Eli Lilly allies itself with Alzheimer's institute in phase III dementia drug trials

Banner Alzheimer's Institute will assist Eli Lilly in its phase III study of the company's Alzheimer's treatment, donanemab.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly has announced a collaboration with Banner Alzheimer's Institute, which specializes in early identification and tracking of the disease, over a phase III trial of its drug donanemab.

Bloomberg News reports that the US pharmaceutical group was awarded breakthrough therapy status for the drug by the US Food and Drug Authority, FDA.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs